|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
|
26765961 |
2016 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs738409 C>G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis.
|
29956823 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we briefly highlight future research that may elucidate the specific mechanisms of the PNPLA3 I148M variant in fibrogenesis, which, in turn, provides a theoretical foundation and valuable experimental data for the clinical management of nonalcoholic fatty liver fibrosis.
|
25624712 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models.
|
28338112 |
2017 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, the common I148M variant of the PNPLA3 gene influencing hepatic lipid metabolism influences HCC risk independently of its effect on the progression of liver fibrosis.
|
25278690 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conversely, this enzymatic activity is markedly reduced with purified PNPLA3 148M, a common mutation robustly associated with liver fibrosis and hepatocellular carcinoma development.
|
24670599 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contradictory data about the impact of the rs738409 steatosis-related polymorphism within PNPLA3 gene on liver fibrosis progression in HIV/hepatitis C virus (HIV/HCV)-coinfected patients have been reported.
|
27973562 |
2016 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients.
|
26760234 |
2016 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism appears to be related to the increased progression of liver fibrosis in HCV infected patients.
|
29674183 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
|
20373368 |
2010 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To perform a comprehensive study on independent modulators of liver fibrosis progression and determinants of portal pressure considering immune status, insulin resistance (IR), serum 25-hydroxyvitamin D (25(OH)D) levels, genetic variants of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and interleukin 28B (IL28B) in a thoroughly documented cohort of HIV/hepatitis C-coinfected (HIV/HCV) patients.
|
24905495 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
|
30139224 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate models adjusting for histologic features of nonalcoholic steatohepatitis and liver fibrosis, PNPLA3 I148M is associated with a decrease in VLDL particle size.
|
28362682 |
2019 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.
|
24978903 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When patients were grouped according to their diabetes status, the PNPLA3 genetic variants were associated with advanced liver fibrosis in diabetic patients only, but not in non-diabetic patients.
|
25457210 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple logistic regression was performed to investigate the association of PNPLA3 G allele with clinical and laboratory variables and with hepatic fibrosis/steatosis.
|
31377187 |
2019 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to assess the impact of IL28B rs8099917 polymorphism on CHC genotype 4 (G4) susceptibility and liver fibrosis progression individually; and in combination with PNPLA3 rs738409.<b>Patients and methods:</b> IL28B rs8099917 and PNPLA3 rs738409 were genotyped in 150 Egyptian CHC patients and 175 healthy controls using real-time PCR.<b>Results:</b> IL28B rs8099917 genotype distribution significantly differs in healthy individuals versus CHC patients (<i>p</i> = .018); and in low versus advanced fibrosis IL28B (<i>p</i> = .013).
|
31793339 |
2019 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 I148M sequence variant favors hepatic lipid accumulation and confers susceptibility to hepatic fibrosis and hepatocellular carcinoma.
|
25171251 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study assessed the contribution of the PNPLA3 rs738409 polymorphism with regard to the steatosis and degree of liver fibrosis in Brazilian patients diagnosed with chronic hepatitis C.
|
29258449 |
2017 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using a newly developed and validated assay for PNPLA3, we explored the prevalence of gene polymorphisms in a cohort of HCV/HIV-coinfected individuals to determine whether there was an association with insulin resistance or hepatic fibrosis.
|
30218427 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 variant was associated with more severe features of steatohepatitis: steatosis (P < 0.001), lobular inflammation (P < 0.001), and ballooning (P = 0.002), but not with liver fibrosis, anthropometry, or insulin resistance.
|
23512881 |
2013 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with both CHB and NAFLD, these genotypes of PNPLA3 polymorphisms were associated with increased susceptibility to nonalcoholic steatohepatitis (NASH) (NAFLD activity score ≥ 3; P = 0.01-0.03) and liver fibrosis (> 1 Metavir grading; P = 0.01-0.04).
|
26229402 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 rs738409 polymorphism is common and may confer a significant risk of NAFLD and advanced liver fibrosis in the Korean population.
|
25069572 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The adiponutrin risk variant is a common genetic determinant of progressive liver fibrosis.
|
21168459 |
2011 |